These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27488535)

  • 41. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects.
    Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD
    Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preconditioning with tin-protoporphyrin IX attenuates ischemia/reperfusion injury in the rat kidney.
    Kaizu T; Tamaki T; Tanaka M; Uchida Y; Tsuchihashi S; Kawamura A; Kakita A
    Kidney Int; 2003 Apr; 63(4):1393-403. PubMed ID: 12631355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
    Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.
    Deel MD; Slemmons KK; Hinson AR; Genadry KC; Burgess BA; Crose LES; Kuprasertkul N; Oristian KM; Bentley RC; Linardic CM
    Clin Cancer Res; 2018 Jun; 24(11):2616-2630. PubMed ID: 29514840
    [No Abstract]   [Full Text] [Related]  

  • 45. MicroRNA-27a Contributes to Rhabdomyosarcoma Cell Proliferation by Suppressing RARA and RXRA.
    Tombolan L; Zampini M; Casara S; Boldrin E; Zin A; Bisogno G; Rosolen A; De Pittà C; Lanfranchi G
    PLoS One; 2015; 10(4):e0125171. PubMed ID: 25915942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.
    Diao Y; Guo X; Jiang L; Wang G; Zhang C; Wan J; Jin Y; Wu Z
    J Biol Chem; 2014 Jan; 289(1):529-39. PubMed ID: 24247238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis.
    Huang HJ; Liu J; Hua H; Li SE; Zhao J; Yue S; Yu TT; Jin YC; Cheng SY
    Oncotarget; 2014 Apr; 5(8):2161-75. PubMed ID: 24811402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
    Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
    J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PAX3-FOXO1: Zooming in on an "undruggable" target.
    Wachtel M; Schäfer BW
    Semin Cancer Biol; 2018 Jun; 50():115-123. PubMed ID: 29146205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.
    Missiaglia E; Shepherd CJ; Aladowicz E; Olmos D; Selfe J; Pierron G; Delattre O; Walters Z; Shipley J
    Cancer Lett; 2017 Jan; 385():251-260. PubMed ID: 27984116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
    Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
    Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
    Hüttner SS; Henze H; Elster D; Koch P; Anderer U; von Eyss B; von Maltzahn J
    Mol Ther; 2023 Sep; 31(9):2612-2632. PubMed ID: 37452493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
    Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
    Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.
    Schmitt-Ney M; Camussi G
    PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
    Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM
    Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of PAX3-FKHR and PAX7-FKHR fusion transcripts in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction using paraffin-embedded tissue.
    Chen BF; Chen ML; Liang DC; Huang YW; Liu HC; Chen SH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Feb; 62(2):86-91. PubMed ID: 10063718
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PAX3-FOXO1 escapes miR-495 regulation during muscle differentiation.
    Xie Z; Tang Y; Su X; Cao J; Zhang Y; Li H
    RNA Biol; 2019 Jan; 16(1):144-153. PubMed ID: 30593263
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Normal and rearranged PAX3 expression in human rhabdomyosarcoma.
    Frascella E; Toffolatti L; Rosolen A
    Cancer Genet Cytogenet; 1998 Apr; 102(2):104-9. PubMed ID: 9546061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
    Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
    Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
    Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
    Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.